Affymetrix (Santa Clara, California) reported entering into a five-year collaboration with Duke University (Durham, North Carolina) to analyze genomic information across large patient samples. Duke researchers will use Affymetrix GeneChip microarray technology to develop new applications for translational research projects. The initial projects will focus on cancer and cardiovascular disease.